FY26 consolidated EBITDA margin expansion of ~200bps YoY
Management reiterated guidance of 200bps margin improvement for the full year, despite a strong Q1.
FORTIS / guidance tracker
Keep management guidance in view.
Fortis Healthcare · forward-looking guidance across the available source record.
Research layer active
Guidance tracker
What management said would happen.
margins
Diagnostics EBITDA margin of 22-23% for FY26
Agilus expects full-year EBITDA margins in the 22-23% range on net revenue basis.
Addition of ~900 beds in FY26, ~50% operationalized this year
Includes brownfield expansions at Noida, Faridabad, FMRI, and Manesar; 250 beds at FMRI to be completed by year-end.
Glen Eagles O&M contract to add ~INR 20-25 crore EBITDA annually
3% of net revenue from ~700 beds; not included in original guidance.
25% EBITDA Margin Target by FY28
Management reiterated its medium-term target of 25% EBITDA margin (including ESOP costs), driven by new facility ramp-up, margin expansion at underperforming hospitals (Manesar, NOIDA), and operational efficiencies.
500 Operational Beds by FY27
Company added 100 beds in Q1 and expects 400 more beds in remaining quarters, with major contribution from FMRI (200 beds pending occupancy certificate) and other brownfield expansions.
ESOP Charge Trajectory
ESOP charge estimated at INR 40 crore per quarter for FY27, declining to INR 30 crore per quarter in FY28 and INR 25 crore per quarter in FY29, based on current vesting schedule.
Agilus Diagnostics FY27 Guidance
Diagnostics business targeting 12-13% revenue growth and 24-25% EBITDA margin, with focus on improving B2C mix and specialized/ preventive portfolio contribution.